ScheefWKleinHOBrockN. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: Preliminary results. Cancer Treat Rep1979; 63: 501–5.
2.
AndrioleGLSandlundJTMiserJS. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. J Clin Oncol1987; 5: 799–803.
3.
PrattCBGorenMP. Ifosfamide/mesna and hematuria. Cancer Treat Rep1987; 71: 1124–5.
4.
LuceJK. Mesna. Background and clinical summary. Columbus, OH: Adria Laboratories, October 4, 1983.
5.
Mesna. Annual report to the Food and Drug Administration. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, January 1986.
6.
ShawICGrahamMI. Mesna. A short review. Cancer Treat Rev1987; 14: 67–86.
7.
GorenMPWrightRKViarMJPrattCB. Renal metabolism and clearance of 2-mercaptopurine sulfonate sodium (mesna) and ifosfamide nephrotoxicity in children with solid tumors (abstract). Proc Am Assoc Cancer Res1987; 28: 192.
